Home » Stocks » VALN

Valneva SE (VALN)

Stock Price: $28.87 USD 0.39 (1.37%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 1.41B
Revenue (ttm) 134.54M
Net Income (ttm) -78.53M
Shares Out 48.94M
EPS (ttm) -1.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $28.87
Previous Close $28.48
Change ($) 0.39
Change (%) 1.37%
Day's Open 28.20
Day's Range 27.88 - 29.11
Day's Volume 5,923
52-Week Range 26.56 - 30.47

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Saint-Herblain (France) – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines...

3 days ago - GlobeNewswire

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines...

4 days ago - GlobeNewswire

Saint-Herblain (France), May 5, 2021 – Valneva SE (the “Company”), a specialty vaccine company focused on the development and commercialization of...

1 week ago - GlobeNewswire

Valneva SE (the “Company”), a specialty vaccine company focused on the development and commercialization of...

2 weeks ago - GlobeNewswire

Valneva SE has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

Valneva on Tuesday reported positive results for its COVID-19 vaccine in early stage clinical trials and said it planned to launch a Phase Three trial this month.

1 month ago - Reuters

About VALN

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. We take a highly specialized and targeted approach to vaccine development, beginning with the identification of deadly and debilitating infectious diseases that lack a prophylactic vaccine solution and for which there are limited therapeutic treatment options. We then apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities... [Read more...]

Industry
Biological Products
IPO Date
May 6, 2021
CEO
Thomas Lingelbach
Employees
579
Stock Exchange
NASDAQ
Ticker Symbol
VALN
Full Company Profile

Financial Performance

In 2020, Valneva's revenue was 110.32 million, a decrease of -12.58% compared to the previous year's 126.20 million. Losses were -64.39 million, 3,592.3% more than in 2019.

Financial numbers in millions EUR.
Financial Statements